Tumors, if you do not suspect, you do not measure
Neuroendocrine tumors and cancers, APTED associations, and AFNEM RENATEN rally to raise awareness, patients and healthcare professionals with neuroendocrine tumors.
The circumstances of discovery of TNE vary depending on the tumor site and in the hormones it produces.
The impact of TNE is increasing worldwide. These cancers usually progress slowly, are difficult to detect and diagnose "if you do not think." The TNE may occur in different parts of the body.
The most frequent sites are gastrointestinal (bowel, pancreas ...), bronchi and lungs, but can also be found in all organs (thyroid, adrenal, kidney ...). TNE can secrete the hormones responsible for the clinical symptoms will be felt by the patient ...
These symptoms may include abdominal pain, flushing, diarrhea, heartburn, weight loss, chronic cough, palpitations ...
Given these clinical manifestations that may exist in many other diseases, including benign, it must evoke a TNE that can be formally diagnosed after conducting further investigations. In addition to this nonspecific symptoms, the chance discovery of the tumor is a common mode of revelation.
On the occasion of the World Day to raise awareness of cancer and neuroendocrine tumors (NET), which took place on 10 November 2012, the President of INCA has supported patient associations and health actors in the fight against these diseases rare.
At the head of the INCA for eighteen months, Dr. Agnes Buzyn infuses dynamism, rigor, clarity and common sense to this benevolent organization which, remember, the main task is to coordinate actions to combat all cancers.
At the heart of the program?
The Cancer Plan, half of which is driven by actions that INCa finance structuring both care delivery and research. Missions large enough to affect areas of prevention, screening for cancer, the organization of care and quality - with best practice recommendations - and, of course, that of research.
Front line? The project calls for "no cancer is left behind."
How the problem of rare tumors is it taken into account by the INCA?
Professor Agnes Buzyn:
This theme was immediately identified as important in the Cancer Plan. It contained a specific part of the recommendations INCa followed. Since 2008, we have implemented project calls for organizing networks involved in the management of these cancers.
Regarding the neuroendocrine tumors, RENATEN network, led by Professor Patricia Niccoli in Marseille, was created as a result of the call for projects. In parallel with the clinical centers network experts who discuss the case of the sick, and offer treatments, there is a network called pathological TENpath whose mission is to confirm the diagnosis by a double reading of the cases. Coordinated by Prof. Jean-Yves Scoazec it supports 1200 new cases per year neuroendocrine tumors.
These clinical networks, largely funded by INCa make recommendations for care treatments that are homogeneous and harmonized in the territory. They must also consider the difficult case consultation meeting multidisciplinary.
All of this is centralized at the national expert center or centers that allow regional experts to discuss all cases. Their mission is also to provide information on these tumors to patients, families, as well as patient organizations. As well as to focus research also dedicated to these rare tumors and, in particular, to find clinical research protocols evaluating new treatments.
Alerts: If you want to know more fresh update helpful articles enter your email address below and be notified by mail.
